CJEU fails to consider primary purpose of SPC Regulation
This article was originally published in SRA
Maria Isabel Manley and Maria Georgiou examine a recent decision by the Court of Justice of the EU on supplementary protection certificates that failed to consider the primary purpose of the SPC Regulation.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.